Status:
COMPLETED
Fibromyalgia Treatment With Enzyme DAO
Lead Sponsor:
Centros de Investigación de Nutrición y Salud
Collaborating Sponsors:
AB Biotek
Conditions:
Fibromyalgia
Eligibility:
FEMALE
30-59 years
Phase:
NA
Brief Summary
Fibromyalgia is a complex and common chronic pain disorder that affects 12 million Europeans. Fibromyalgia causes persistent widespread pain in muscles, tendons, ligaments, and joints, as well as wide...
Eligibility Criteria
Inclusion
- Female
- Age between 30 and 59 years (included)
- Diagnosis of fibromyalgia
- Must sign an informed consent
- Able to follow-up at 2 and 6 months
Exclusion
- Pregnant or possibly pregnant
- Patients with change of pharmacological treatment in the last 3 months
- Patients with DAO enzyme treatment
- Patients diagnosed with other severe diseases (i.e. cancer, cardiovascular disease, autoimmune disease or metabolic disease)
- Patients with multiple chemical sensitivity
Key Trial Info
Start Date :
February 22 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 18 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05389761
Start Date
February 22 2022
End Date
November 18 2022
Last Update
March 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Ruber Internacional
Madrid, Spain, 28036